Global access to cancer precision medicine faces a stark divide as biomarker trials concentrate heavily in high-income nations, according to a report from The Lancet Oncology Commission. While global spending on cancer drugs surged 75% over the five years leading up to 2024 to reach $252,000,000,000—and is projected to climb to $441,000,000,000 within three years—low- and middle-income countries host just 2% of biomarker cancer trials compared to 81% in wealthy nations.
Global Disparities in Biomarker Testing and Clinical Trials
The Lancet Oncology Commission report highlights deep structural inequalities in how patients access modern cancer treatments. Precision oncology relies on analyzing the genetic characteristics of a tumor to select the most effective drug for an individual patient. Yet, high costs, restricted availability of advanced genetic testing, and expensive medications create barriers across developing healthcare systems. Approximately 7,000,000 to 8,000,000 people globally require standard molecular testing each year. Among them, roughly 314,000 women diagnosed with ovarian cancer qualify for BRCA testing, but nearly half of those in low- and middle-income countries miss out entirely due to low availability.
To address these gaps, the commission established a framework for prioritizing molecular testing and associated therapies alongside a system readiness assessment tool. The ten core recommendations aim to integrate precision oncology fairly and responsibly into broader cancer control strategies and universal health coverage.
Policy Solutions and Government Initiatives in India
Indian oncology researcher Bhawna Sirohi emphasizes that India requires a five-year policy agenda to boost both the accessibility and affordability of precision oncology. Government programs are beginning to tackle these infrastructure challenges directly. Supported by the Indian Council of Medical Research, the DIAMOnDS project works to strengthen advanced molecular oncology diagnostics by offering free testing services. The initiative currently targets specific markers in lung cancer, breast cancer, and select blood cancers utilizing technologies such as real-time polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridisation.
At the same time, Minister of State for Science and Technology Jitendra Singh points to the future role of nanomedicine in personalizing healthcare. Nanomedicine applies nanotechnology to medical interventions at the cellular and molecular scale to improve treatment efficiency while cutting costs. Singh cautions, however, that artificial intelligence and nanotechnology must serve strictly as tools to support a physician’s clinical judgment and experience rather than replace human expertise. He advocates for reforms in medical education to safeguard core clinical skills while adopting new technologies.
Comparison of Global Spending and Trial Access
| Metric | Low- and Middle-Income Countries | High-Income Countries |
|---|---|---|
| Biomarker Cancer Trials Share | ~2% | 81% |
| Global Cancer Drug Spending (2024) | $252,000,000,000 (Global Total) | |
| Projected Spending (Three-Year Outlook) | $441,000,000,000 (Global Total) | |
Precision oncology and biomarker trial challenges in developing nations
What is precision oncology?
Precision oncology is a personalized approach to cancer treatment that analyzes the unique genetic profile of a patient’s tumor to select the most effective targeted therapy.
Why are biomarker trials limited in developing nations?
Low- and middle-income countries face severe financial, technological, and infrastructural constraints that limit advanced genetic testing and clinical trial placement, leaving roughly 2% of such trials in those regions.
What technologies are used in India’s DIAMOnDS project?
The project utilizes real-time PCR, immunohistochemistry, and fluorescence in situ hybridisation to provide free diagnostic services for lung, breast, and specific blood cancers.
Related reading